{
    "id": 24619,
    "fullName": "JAK3 L857P",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "JAK3 L857P lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). L857P results in cytokine receptor complex-independent activation of Jak3 and increased cell proliferation in culture (PMID: 26446793).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 6343,
                    "pubMedId": 26446793,
                    "title": "Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26446793"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3718,
        "geneSymbol": "JAK3",
        "terms": [
            "JAK3",
            "JAK-3",
            "JAK3_HUMAN",
            "JAKL",
            "L-JAK",
            "LJAK"
        ]
    },
    "variant": "L857P",
    "createDate": "07/20/2016",
    "updateDate": "10/07/2018",
    "referenceTranscriptCoordinates": {
        "id": 93637,
        "transcript": "NM_000215",
        "gDna": "chr19:g.17832629A>G",
        "cDna": "c.2570T>C",
        "protein": "p.L857P",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7408,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793).",
            "molecularProfile": {
                "id": 25367,
                "profileName": "JAK3 L857P"
            },
            "therapy": {
                "id": 941,
                "therapyName": "Tofacitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6343,
                    "pubMedId": 26446793,
                    "title": "Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26446793"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7402,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing JAK3 L857P demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793).",
            "molecularProfile": {
                "id": 25367,
                "profileName": "JAK3 L857P"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6343,
                    "pubMedId": 26446793,
                    "title": "Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26446793"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7404,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793).",
            "molecularProfile": {
                "id": 25367,
                "profileName": "JAK3 L857P"
            },
            "therapy": {
                "id": 2809,
                "therapyName": "NIBR3049",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6343,
                    "pubMedId": 26446793,
                    "title": "Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26446793"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7405,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing both JAK3 L857P and Y100A in culture (PMID: 26446793).",
            "molecularProfile": {
                "id": 25374,
                "profileName": "JAK3 Y100A JAK3 L857P"
            },
            "therapy": {
                "id": 2809,
                "therapyName": "NIBR3049",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6343,
                    "pubMedId": 26446793,
                    "title": "Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26446793"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7409,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing both JAK3 L857P and Y100A in culture (PMID: 26446793).",
            "molecularProfile": {
                "id": 25374,
                "profileName": "JAK3 Y100A JAK3 L857P"
            },
            "therapy": {
                "id": 941,
                "therapyName": "Tofacitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6343,
                    "pubMedId": 26446793,
                    "title": "Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26446793"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7403,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing both JAK3 L857P and JAK3 Y100A demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793).",
            "molecularProfile": {
                "id": 25374,
                "profileName": "JAK3 Y100A JAK3 L857P"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6343,
                    "pubMedId": 26446793,
                    "title": "Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26446793"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25367,
            "profileName": "JAK3 L857P",
            "profileTreatmentApproaches": [
                {
                    "id": 10381,
                    "name": "JAK3 Inhibitor - ATP competitive",
                    "profileName": "JAK3 L857P"
                },
                {
                    "id": 10378,
                    "name": "JAK Inhibitor (Pan)",
                    "profileName": "JAK3 L857P"
                },
                {
                    "id": 10379,
                    "name": "JAK Inhibitor (Pan) - ATP competitive",
                    "profileName": "JAK3 L857P"
                },
                {
                    "id": 10380,
                    "name": "JAK3 Inhibitor",
                    "profileName": "JAK3 L857P"
                }
            ]
        },
        {
            "id": 25374,
            "profileName": "JAK3 Y100A JAK3 L857P",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 93637,
            "transcript": "NM_000215",
            "gDna": "chr19:g.17832629A>G",
            "cDna": "c.2570T>C",
            "protein": "p.L857P",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}